Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 15;10:297. doi: 10.1038/s41598-019-57233-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

DSS-induced colitis model. Bodyweight changes (A), representative gross photos of the colorectal area (B), inflammation scores (C), and representative microscopic images of histopathological examination (x200) (D) after administration of DSS for wild-type and Il17a^−/− mice (wild-type mice without DSS: n = 5; wild-type mice with DSS: n = 8; Il17a^−/− mice without DSS: n = 7; Il17a^−/− mice with DSS: n = 9). Bodyweight changes (E), representative gross photos of the colorectal area (F), and representative microscopic images of histopathological examination (x200) (G) according to administration of anti-IL-17A antibody (wild-type mice without DSS: n = 3; wild-type mice with DSS: n = 3; wild-type mice with anti-IL-17A antibody and DSS: n = 4). In the anti-IL-17A antibody group, 100 μL of secukinumab was injected intraperitoneally three times per week starting two weeks before DSS administration, continuing until the end of the experiment. Bars represent standard errors. * P < 0.05, ** P < 0.01. DSS, dextran sulfate sodium; NS, not significant.